Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312

NCT00422175 | Completed Phase 1

• 1 other identifier: CBAF312A2101
• Study Type: interventional
• Target: 63
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the safety, tolerability, and effect of oral BAF312 on bodily functions as well as the body's absorption, distribution, metabolism, and excretion of BAF312 in healthy volunteers

Conditions

Healthy

Keywords

Safety, tolerability, pharmacokinetics, pharmacodynamics, oral, BAF312, healthy volunteers

Outcome Measures

Primary Outcomes (2)

• safety, tolerability, and pharmacokinetic profile

• Maximum Tolerated Dose

Secondary Outcomes (3)

• Lymphocyte counts and lymphocyte recovery period

• Cardiac rate and rhythm

• Pulmonary function

Interventions

BAF 312 DRUG

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female subjects, 18 to 55 years of age included, and in good health
• Female subjects must be either surgically sterilized at least 6 months prior to study participation or post-menopausal (no regular menstrual bleeding for at least 1 years)
• Female subjects test are required to have a negative result for a pregnancy test, not be lactating/breast feeding, and must either:
• Body mass index (BMI) must be within the range of 18 to 30 Kg/m2. Subjects must weigh at least 50 kg to participate in this study.
• Able to communicate with the investigator, to understand and comply with the requirements of the study
• Understand and sign the written informed consent firm

You may not qualify if:

• Smokers
• Subjects who received live vaccine 4 weeks prior to dosing.
• Use of any prescription drugs four weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two weeks prior to dosing. Acetaminophen is acceptable
• Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
• Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
• Significant illness within two weeks prior to dosing.
• A past personal or close family medical history of clinically significant cardiac abnormalities
• History of Acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease) Clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis) Known hypersensitivity or severe adverse event to darifenacin or similar drugs Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize participation in the study Immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result. Drug or alcohol abuse

Sponsors & Collaborators

• Novartis: lead

Study Sites (1)

Novartis

East Hanover, New Jersey, United States

Location

MeSH Terms

Interventions

siponimod

Study Officials

• Novartis

  Investigative site

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: January 11, 2007
• First Posted: January 15, 2007
• Study Start: October 1, 2006
• Study Completion: November 1, 2007
• Last Updated: November 29, 2007

Record last verified: 2007-11

Locations

US (1)